Table 5.

Clinical initiatives to address e-cigarette or vaping product use–associated lung injury

1.Clinical training in evaluating patient exposures is needed to ensure that comprehensive assessments of vaping product exposures are thoroughly conducted. 2.Prospective clinical studies are needed to enroll, study, and follow patients with EVALI to create better standardized diagnosis and treatment protocols as well as learn more about long-term outcomes. 3.Standardized follow-up assessments and timing are needed to ensure comparability across follow-up studies to better characterize the risks of long-term EVALI-related disease. 4.Consensus on therapeutic management algorithms is needed. 5.Consensus is needed on diagnostic criteria to define EVALI, particularly an update to CDC guidelines that requires exclusion of COVID-19.

Definition of abbreviations: CDC = U.S. Centers for Disease Control and Prevention; COVID-19 = coronavirus disease; EVALI = e-cigarette or vaping product use–associated lung injury.